CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial

Regan, Meredith M; Leyland-Jones, Brian; Bouzyk, Mark; Pagani, Olivia; Tang, Weining; Kammler, Roswitha; Dell'orto, Patrizia; Biasi, Maria Olivia; Thürlimann, Beat; Lyng, Maria B; Ditzel, Henrik J; Neven, Patrick; Debled, Marc; Maibach, Rudolf; Price, Karen N; Gelber, Richard D; Coates, Alan S; Goldhirsch, Aron; Rae, James M; Viale, Giuseppe; Breast International Group (BIG) 1-98 Collaborative Group,

doi:10.1093/jnci/djs125

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial

Author:

Regan, Meredith M

Leyland-Jones, Brian ; Bouzyk, Mark ; Pagani, Olivia ; Tang, Weining ; Kammler, Roswitha ; Dell'orto, Patrizia ; Biasi, Maria Olivia ; Thürlimann, Beat ; Lyng, Maria B ; Ditzel, Henrik J ; Neven, Patrick ; Debled, Marc ; Maibach, Rudolf ; Price, Karen N ; Gelber, Richard D ; Coates, Alan S ; Goldhirsch, Aron ; Rae, James M ; Viale, Giuseppe ; Breast International Group (BIG) 1-98 Collaborative Group,

Keywords:

Aged, Antineoplastic Agents, Hormonal, Aromatase Inhibitors, Breast Neoplasms, Cytochrome P-450 CYP2D6, Disease-Free Survival, Drug Administration Schedule, Female, Genotype, Humans, International Cooperation, Kaplan-Meier Estimate, Middle Aged, Nitriles, Polymerase Chain Reaction, Polymorphism, Genetic, Polymorphism, Single Nucleotide, Postmenopause, Tamoxifen, Treatment Outcome, Triazoles, Science & Technology, Life Sciences & Biomedicine, Oncology, HOT FLASHES, AROMATASE INHIBITORS, METABOLITE, THERAPY, RECURRENCE, ENDOXIFEN, RISK, BIOTRANSFORMATION, PHARMACOGENETICS, ASSOCIATION, Letrozole, Breast International Group (BIG) 1-98 Collaborative Group, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, 3211 Oncology and carcinogenesis

Abstract:

Adjuvant tamoxifen therapy is effective for postmenopausal women with endocrine-responsive breast cancer. Cytochrome P450 2D6 (CYP2D6) enzyme metabolizes tamoxifen to clinically active metabolites, and CYP2D6 polymorphisms may adversely affect tamoxifen efficacy. In this study, we investigated the clinical relevance of CYP2D6 polymorphisms.